» Articles » PMID: 21985151

A Novel Bacteriophage Tail-Associated Muralytic Enzyme (TAME) from Phage K and Its Development into a Potent Antistaphylococcal Protein

Overview
Journal BMC Microbiol
Publisher Biomed Central
Specialty Microbiology
Date 2011 Oct 12
PMID 21985151
Citations 39
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Staphylococcus aureus is a major cause of nosocomial and community-acquired infections. However, the rapid emergence of antibiotic resistance limits the choice of therapeutic options for treating infections caused by this organism. Muralytic enzymes from bacteriophages have recently gained attention for their potential as antibacterial agents against antibiotic-resistant gram-positive organisms. Phage K is a polyvalent virulent phage of the Myoviridae family that is active against many Staphylococcus species.

Results: We identified a phage K gene, designated orf56, as encoding the phage tail-associated muralytic enzyme (TAME). The gene product (ORF56) contains a C-terminal domain corresponding to cysteine, histidine-dependent amidohydrolase/peptidase (CHAP), which demonstrated muralytic activity on a staphylococcal cell wall substrate and was lethal to S. aureus cells. We constructed N-terminal truncated forms of ORF56 and arrived at a 16-kDa protein (Lys16) that retained antistaphylococcal activity. We then generated a chimeric gene construct encoding Lys16 and a staphylococcal cell wall-binding SH3b domain. This chimeric protein (P128) showed potent antistaphylococcal activity on global clinical isolates of S. aureus including methicillin-resistant strains. In addition, P128 was effective in decolonizing rat nares of S. aureus USA300 in an experimental model.

Conclusions: We identified a phage K gene that encodes a protein associated with the phage tail structure. The muralytic activity of the phage K TAME was localized to the C-terminal CHAP domain. This potent antistaphylococcal TAME was combined with an efficient Staphylococcus-specific cell-wall targeting domain SH3b, resulting in the chimeric protein P128. This protein shows bactericidal activity against globally prevalent antibiotic resistant clinical isolates of S. aureus and against the genus Staphylococcus in general. In vivo, P128 was efficacious against methicillin-resistant S. aureus in a rat nasal colonization model.

Citing Articles

Phage-Derived Endolysins Against Resistant Staphylococcus spp.: A Review of Features, Antibacterial Activities, and Recent Applications.

Golban M, Charostad J, Kazemian H, Heidari H Infect Dis Ther. 2024; 14(1):13-57.

PMID: 39549153 PMC: 11782739. DOI: 10.1007/s40121-024-01069-z.


Pharmacokinetics and Biodistribution of Phages and their Current Applications in Antimicrobial Therapy.

Kang D, Bagchi D, Chen I Adv Ther (Weinh). 2024; 7(3).

PMID: 38933919 PMC: 11198966. DOI: 10.1002/adtp.202300355.


LYZ2-SH3b as a novel and efficient enzybiotic against methicillin-resistant Staphylococcus aureus.

Asadi M, Taheri-Anganeh M, Ranjbar M, Khatami S, Maleksabet A, Mostafavi-Pour Z BMC Microbiol. 2023; 23(1):257.

PMID: 37704938 PMC: 10500863. DOI: 10.1186/s12866-023-03002-9.


New Strategies to Kill Metabolically-Dormant Cells Directly Bypassing the Need for Active Cellular Processes.

Stojowska-Swedrzynska K, Kuczynska-Wisnik D, Laskowska E Antibiotics (Basel). 2023; 12(6).

PMID: 37370363 PMC: 10295454. DOI: 10.3390/antibiotics12061044.


Therapeutic potential of bacteriophage endolysins for infections caused by Gram-positive bacteria.

Liu H, Hu Z, Li M, Yang Y, Lu S, Rao X J Biomed Sci. 2023; 30(1):29.

PMID: 37101261 PMC: 10131408. DOI: 10.1186/s12929-023-00919-1.


References
1.
Hogue J, Buttke P, Braun L, Fairchok M . Mupirocin resistance related to increasing mupirocin use in clinical isolates of methicillin-resistant Staphylococcus aureus in a pediatric population. J Clin Microbiol. 2010; 48(7):2599-600. PMC: 2897475. DOI: 10.1128/JCM.02118-09. View

2.
Lamers R, Stinnett J, Muthukrishnan G, Parkinson C, Cole A . Evolutionary analyses of Staphylococcus aureus identify genetic relationships between nasal carriage and clinical isolates. PLoS One. 2011; 6(1):e16426. PMC: 3025037. DOI: 10.1371/journal.pone.0016426. View

3.
Shinomiya T, Shiga S . Bactericidal activity of the tail of Pseudomonas aeruginosa bacteriophage PS17. J Virol. 1979; 32(3):958-67. PMC: 525945. DOI: 10.1128/JVI.32.3.958-967.1979. View

4.
Fischetti V . Bacteriophage lytic enzymes: novel anti-infectives. Trends Microbiol. 2005; 13(10):491-6. DOI: 10.1016/j.tim.2005.08.007. View

5.
Caldentey J, Bamford D . The lytic enzyme of the Pseudomonas phage phi 6. Purification and biochemical characterization. Biochim Biophys Acta. 1992; 1159(1):44-50. DOI: 10.1016/0167-4838(92)90073-m. View